- CEO
- Sheng Li Hu
- Full Time Employees
- 5,339
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Changsha China
- IPO Date
- Dec 7, 2021
- Business
- Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. is a China-based integrated healthcare and pharmaceutical enterprise engaged in pharmaceutical distribution, specialized retail pharmacy operations, pharmaceutical research and manufacturing, and medical healthcare services. Founded in 2002 and headquartered in Changsha, Hunan Province, the company operates across the healthcare value chain through four principal business divisions: Pharmaceutical Distribution, Pharmaceutical Retail, Pharmaceutical Manufacturing, and Medical Services.
In its Pharmaceutical Distribution division, the company engages in the wholesale, logistics, and supply chain distribution of prescription medications, over-the-counter drugs, biopharmaceuticals, traditional Chinese medicines, medical devices, diagnostic reagents, and consumables to public hospitals, grassroots healthcare centers, and medical institutions primarily throughout Hunan Province. In its Pharmaceutical Retail division, the company manages an extensive network of retail pharmacies, specialized Direct-to-Patient pharmacies, and designated chronic disease pharmacies, providing high-value specialty pharmaceuticals for oncology, immunology, and rare diseases, alongside prescription filling, health consultation, disease management, and online-to-offline retail pharmaceutical services. In its Pharmaceutical Manufacturing division, through operating subsidiaries including Dajia Weikang Biopharmaceutical Co., Ltd. and Hunan Tianji Caotang Pharmaceutical Co., Ltd., the company develops, produces, and commercializes chemical pharmaceuticals, traditional Chinese medicines, and health formulations; core manufactured products include Xiaojianzhong granules; Jiuwei Gantai capsules; Azithromycin granules; Qingre Sanjie capsules; Naodesheng pills; and various dosage forms across cardiovascular, digestive, anti-infective, and respiratory therapeutic categories, supplemented by medical devices, dietary supplements, cosmetics, and disinfectant products. In its Medical Services division, the company operates specialized medical institutions, including the Changsha Jiachen Reproductive and Genetics Hospital, offering assisted reproductive technologies, genetic diagnosis, chronic disease rehabilitation, and specialized clinical care.
In recent developments, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. has expanded its geographic footprint beyond Hunan Province through a series of retail pharmacy chain acquisitions across China, securing controlling interests in regional chains including Ningxia Delixin Pharmacy Co., Ltd., Yinchuan Meihetai Pharmaceutical Chain Co., Ltd., Shanxi Simaile Pharmacy Chain Co., Ltd., and Anhui Dajiaweikang Health Pharmacy Co., Ltd., while integrating traditional Chinese medicine manufacturing through the acquisition of Hunan Tianji Caotang Pharmaceutical Co., Ltd. Additionally, the company established a specialized Silver Economy Business Division to expand integrated medical and elder care solutions, accelerated research and development in regenerative medicine and cell therapy through dedicated research institutes, implemented centralized supply chain and digital transformation initiatives across acquired retail networks, and executed corporate share repurchase programs to support long-term capital management.